semaglutide covered by medi-cal 🚨 California Alert: Coverage for Obesity Medications at Risk Just two years after began covering FDA-approved GLP-1 medications for obesity, that coverage is set to end in January 2026 — a 💉 GLP-1 Medications Available at

While formal evidence remains in development, the mechanistic rationale is compelling: sustained, gentle GLP-1 receptor activation may favorably influence glucose metabolism, cardiovascular integrity, and neuroprotection, all while maintaining tolerability and adherence

Effects of 12 weeks of endurance training on bone mineral content and bone mineral density in obese, overweight and normal weight adolescent girls

Through comprehensive assessments, ongoing monitoring, and compassionate care, our team supports patients with clear, evidence-based recommendations designed to promote safety, sustainability, and long-term wellness

CDC Vaccines

Despite this potential, given the known long-term benefit of lowering hemoglobin A1c in preventing DR progression, there does not appear to be any contraindication to initiating GLP-1/GIP agonist therapy with appropriate ocular monitoring

Its a question our team at Real Peptides hears all the time